Navigation Links
New advance announced in reducing 'bad' cholesterol
Date:12/8/2011

Scientists from the University of Leicester and University of California Los Angeles (UCLA) have announced a breakthrough advance in tackling dangerous 'bad' cholesterol in the body.

They have filed two patents for developing targeted drugs that would act as a catalyst for lowering levels of 'bad' cholesterol.

Two research papers published by the academics enhance the understanding of the regulation of low-density lipoprotein (LDL) or "bad" cholesterol.

LDL, the so-called "bad" cholesterol, is often linked to medical problems like heart disease, stroke and clogged arteries.

In the body, cells in the liver produce an LDL receptor that binds LDL and removes it from the blood, thereby lowering cholesterol levels.

However, the LDL receptors can be hindered from their mission.

The scientists found that an enzyme called IDOL has been shown to play a key and specific role in the ability of the LDL receptor to bind with 'bad' cholesterol. Therefore targeting the enzyme with drugs would assist the LDL receptors in lowering circulating cholesterol in humans.

Professor John Schwabe, Head of Biochemistry at the University of Leicester, said: "Development of a drug that interferes with IDOL's activity could help lower levels of LDL. Our research has greatly enhanced our understanding of this important process."

Prof John Schwabe, Dr Ben Goult and Dr Louise Fairall at the University of Leicester in collaboration with the University of California Los Angeles (UCLA) published their research in Genes & Development and the Proceeds of the National Academy of Science (PNAS) . The research in the UK was funded by the Wellcome Trust and in the US by NIH and the National Heart Foundation of Australia Overseas Fellowship.

The study in Genes & Development announced the first atomic structural information on IDOL and identified the E2 ligase, UBE2D that works with IDOL to degrade the LDL receptor.
'/>"/>

Contact: Prof. John Schwabe
js336@leicester.ac.uk
01-162-297-030
University of Leicester
Source:Eurekalert  

Page: 1 2

Related biology news :

1. UCSB scientists make advances in neuroscience and vision research
2. Roche NimbleGen and BGI develop advanced MHC region capture technology for biomedical research
3. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
4. Bats, dolphins, and mole rats inspire advances in ultrasound technology
5. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
6. Iowa State engineers establish national panel to advance a carbon negative economy
7. Advanced Medical Care for At-Risk Newborns Nets Economic Benefits
8. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
9. An IRB Barcelona project on computational biology receives an ERC Advanced Grant
10. Advance toward a breath test to diagnose multiple sclerosis
11. Leaf litter ants advance case for rainforest conservation in Borneo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New advance announced in reducing 'bad' cholesterol
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... Ume University, Sweden, have explored two different ways ... sequence leading to the formation of oxygen molecules ... in the scientific journal Nature Communications . ... day synthetic catalysts for water oxidation, which are ... the direct storage of solar energy in fuels ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... While endogenous estrogen (i.e., estrogen produced by ovaries and ... hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous ... risk, according to study results presented at the 33rd ... 8-12. "Our analysis suggests that, contrary to ...
... federal government, now fund the majority of human embryonic stem ... recent study in the journal Nature Biotechnology . ... they prioritized human embryonic stem cell research, and much of ... funded by the National Institutes of Health under federal guidelines ...
... Winter graduation deadlines have spurred a flurry of ... (STEM). However, for many women and students from underrepresented ... fellowship to faculty appointment in STEM is one of ... combat the loss of diversity in STEM fields, a ...
Cached Biology News:Estrogen alone is effective for reducing breast cancer risk 2States now fund majority of human embryonic stem cell research 2STEM workshop set to advance women, minorities 2
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... 2014 Using microscopic polymer light resonators that ... at MIT,s Quantum Photonics Laboratory have developed new ... parts-per-billion range. Optical sensors are ideal for detecting ... ratio, compact, lightweight nature, and immunity to electromagnetic ... been developed before, the MIT team conceived an ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... YORK, Aug. 31 Reportlinker.com announces that a ... catalogue: Women,s Infertility - Pipeline ... http://www.reportlinker.com/p0286181/Women,s-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Women,s ... 2017 SummaryGlobalData, the industry analysis ...
... 31 Reportlinker.com announces that a ... in its catalogue: ... for Monoclonal Antibodies and Recombinant Proteins ... Production Technologies ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 2Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 3Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 4Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 5Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 7Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 8Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 9Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 10Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 11
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
... wide and long electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5 ...
... are derived from frozen embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... are large (3-5mm in diameter) in comparison ...
Biology Products: